Raymond James analyst Danielle Brill downgraded FibroGen (NASDAQ: FGEN) from Outperform to Market Perform.The analyst commented, "We are downgrading Fibrogen ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE